肿瘤患者红细胞CR1基因组密度多态性的变化  

Changes of CR1 genomic density polymorphism of red cells in patients with malignancy

作　　者：郭峰[1,2] 张俊洁[1,2] 赵书平 邬伟秀[1,2] 

机构地区：[1]上海第二军医大学长海医院免疫室 [2]上海第一人民医院血液科

出　　处：《中华微生物学和免疫学杂志》1998年第4期282-285,共4页Chinese Journal of Microbiology and Immunology

基　　金：国家自然科学基金

摘　　要：目的研究恶性肿瘤患者红细胞ＣＲ１基因组密度多态性变化规律。方法采用ＰＣＲ和ＨｉｎｄⅢ酶切技术对恶性肿瘤红细胞ＣＲ１基因组密度多态性变化进行研究。结果１６４例恶性肿瘤患者红细胞ＣＲ１基因突变率４１．５％，明显高于１８９例正常人群（２１％），特别是年轻恶性肿瘤患者红细胞ＣＲ１基因点突变率可达６６．７％（２１例中），明显高于年轻正常人群（１９．８％，９６例）。在恶性肿瘤患者中红细胞ＣＲ１基因ＨＨ型的红细胞ＣＲ１活性高于红细胞ＣＲ１基因ＬＬ型患者，但低于正常人红细胞ＣＲ１活性。结论这些结果表明，红细胞ＣＲ１基因点突变率升高与免疫发病机理有相关性。Objective To study the change regularity of red cell CR1 genomic density polymorphism in patients with malignancy (164 cases). Methods Polymerase chain reaction (PCR) and Hind Ⅲ restriction enzyme digestion was used to study the change of erythrocyte CR1(ECR1) genomic density polymorphism in patients with malignancy. Results The spot mutation rate (41.5%) of ECR1 density gene (ECR1 gene) in patients with malignancy (164 cases) was higher than that (21%) in normal people (189 cases, P <0.001), especially the spot mutation rate (66.7%) of ECR1 gene in young patients with malignancy (21 cases) is higher than that (19.8%) in normal young people (96 cases).In patients with malignancy, CR1 activity in CR1 gene HH type was higher than that in ECR1 gene LL type. Conclusions These results can indicate that the spot mutation of ECR1 gene in young patients with malignancy may be related to immunopathological mechanism.

关 键 词：肿瘤 红细胞 CR1基因 多态现象 

分 类 号：R730.23[医药卫生—肿瘤]